Biosergen AS appoints Gunilla Ekström as CEO

TRONDHEIM October 11, 2012. Biosergen AS, a Karolinska Development  portfolio company, announced today the appointment of Gunilla Ekström as new CEO.“We are very pleased to have appointed Gunilla Ekström as our new CEO in Biosergen AS”, says Ola Flink, Chairman of Biosergen. “Gunilla Ekström has more than 20 years of experience from the pharmaceutical industry. Her broad knowledge in all stages of pharmaceutical development will be of great benefit to the company.” Biosergen has developed a series of novel polyene macrolide antifungals with unique properties. The lead compound BSG005,